Hostname: page-component-7479d7b7d-c9gpj Total loading time: 0 Render date: 2024-07-10T13:59:12.691Z Has data issue: false hasContentIssue false
  • English
  • Français

Cholinesterase-inhibitor Therapy for Dementia: Novel Clinical Substrates and Mechanisms for Treatment Response

Published online by Cambridge University Press:  07 November 2014

Daniel I. Kaufer
Get access Rights & Permissions [Opens in a new window]

Abstract

Historically, drugs that increase central cholinergic transmission have primarily been investigated for relieving cognitive symptoms in mild-to-moderate Alzheimer's disease. These efforts have led to the somewhat unexpected findings that cholinergic therapy has a beneficial effect on selected neuropsychiatric symptoms in AD across disease stages. In Parkinson's disease with dementia and dementia with Lewy bodies, cholinergic deficits are more severe than in AD, and there is emerging evidence that cholinesterase inhibitors are efficacious in treating core symptoms of attentional disturbance and psychosis. Recent data also suggest a rational basis for cholinergic therapy in vascular dementia. The cognitive and neuropsychiatric effects of cholinergic therapy observed in AD and other dementias form the crux of an integrative model of cholinergic therapeutic efficacy that encompasses the diverse central nervous system actions of acetylcholine and its complementary interactions with central monoamine transmitters. This heuristic framework highlights the broader therapeutic potential of cholinergic therapy for symptom-based indications in other neuropsychiatric disorders.

Type
Feature Articles
Information
CNS Spectrums , Volume 7 , Issue 10: Geriatric Psychiatry: Emerging Concepts , October 2002 , pp. 742 - 750
Copyright
Copyright © Cambridge University Press 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Cooper, JR, Bloom, FE, Roth, RH. The Biochemical Basis of Neuropharmacobgy. 7th ed. New York, NY: Oxford University Press; 1996.Google Scholar
2.Mesulam, MM. Structure and function of cholinergic pathways in the cerebral cortex, limbic system, basal ganglia, and thalamus of the human brain. In: Bloom, FE, Kupfer, DJ, eds. Psychopharmacology: The Fourth Generation of Progress. Baltimore, MD: Raven Press; 1995:135–146.Google Scholar
3.Geula, C. Abnormalities of neural circuitry in Alzheimer's disease: hippocampus and cortical cholinergic innervation. Neurology 1998;51(suppl 1):S18–29.CrossRefGoogle ScholarPubMed
4.Selden, NR, Gitelman, DR, Salamon-Murayama, N, Parrish, TB, Mesulam, MM. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain. 1998;121:2249–2257.CrossRefGoogle ScholarPubMed
5.Ehlert, FJ, Roeske, WR, Yamamura, HI. Molecular biology, pharmacology, and brain distribution of subtypes of the muscarinic receptor. In: Bloom, FE, Kupfer, DJ, eds. Psychopharmacology: The Fourth Generation of Progress. Baltimore, MD: Raven Press; 1995:111–124.Google Scholar
6.Arneric, SP, Sullivan, JP, Williams, M. Neuronal nicotinic acetylcholine receptors: Novel targets for central nervous system therapeutics. In: Bloom, FE, Kupfer, DJ, eds. Psychopharmacology: The Fourth Generation of Progress. Baltimore, MD: Raven Press; 1995:95–110.Google Scholar
7.Decker, MW, Brioni, JD. Neuronal nicotinic receptors: Potential treatment of Azheimer's disease with novel cholinergic channel modulators. In: Brioni, JD, Decker, MW, eds. Pharmacobgical treatment of Alzheimer's Disease: Molecular and Neurobiological Foundations. New York, NY: Wiley-Liss; 1997:433–459.Google Scholar
8.Davis, KL, Mohs, RC, Marin, D, et al.Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999;281:1401–1406.CrossRefGoogle ScholarPubMed
9.DeKosky, ST, Ikonomovic, MD, Styren, SD, et al.Upregulation of choline acetylcholinestrase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145–155.CrossRefGoogle Scholar
10.Procter, AW, Lowe, SL, Palmer, AM, et al.Topographical distribution of neurochemical changes in Alzheimer's disease. J Neurol Sci. 1988;84:125–140.CrossRefGoogle ScholarPubMed
11.Mesulam, M. Neuroanatomy of cholinesterases in the normal human brain and Alzheimer's disease. In: Giacobini, E, ed. Cholinesterases and Cholinesterase Inhibitors. London, England: Martin Dunitz; 2000:121–137.Google Scholar
12.Newhouse, PA, Potter, A, Levin, ED. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Drugs Aging. 1997;11:206–228.CrossRefGoogle ScholarPubMed
13.Cutler, NR, Sramek, JJ. Muscarinic MI-receptor agonists: potential in the treatment of Alzheimer's disease. CNS Drugs. 1995;3:467–481.CrossRefGoogle Scholar
14.Francis, PT, Palmer, AM, Snape, M, Wilcock, GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66:137–147.CrossRefGoogle ScholarPubMed
15.Sarter, M, Bruno, J. Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Brain Res Rev. 1997;23:28–46.CrossRefGoogle Scholar
16.Perry, E, Walker, M, Grace, J, Perry, R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 1999;22:273–280.CrossRefGoogle ScholarPubMed
17.Lawrence, AD, Sahakian, BJ. The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems. Neurochem Res. 1998; 23:787–794.CrossRefGoogle ScholarPubMed
18.Palmer, AM, DeKosky, ST. Monoamine neurons in aging and Alzheimer's disease. J Neural Transm Gen Sect. 1993;91:135–159.CrossRefGoogle ScholarPubMed
19.Raskind, MA, Peskind, ER. Neurologic bases of noncognitive behavioral problems in Alzheimer's disease. Alzheimer Dis Assoc Disord. 1994;8(suppl 3):54–60CrossRefGoogle Scholar
20.Cummings, JL, Kaufer, DI. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology. 1996;47:876–883.CrossRefGoogle ScholarPubMed
21.Kaufer, DI. Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase-inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord. 1998;(suppl 2):8–14.CrossRefGoogle ScholarPubMed
22.Cummings, JL. Cholinesterase-inhibitors: a new class of psychotropic compounds. Am J Psychiatry. 2000;157:4–15.CrossRefGoogle ScholarPubMed
23.Physicians Desk Reference, 55th ed. Montvale, NJ: Medical Economics Co., Inc.; 2001.Google Scholar
24.Knapp, MJ, Knopman, DS, Solomon, PR, et al.A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA. 1994;271:985–991.CrossRefGoogle ScholarPubMed
25.Rogers, SL, Friedhoff, LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia. 1996;7:292–303.Google ScholarPubMed
26.Corey-Bloom, J, Anand, R, Veach, J, A randomized trial evaluating the efficacy and safety of ENA-713, a new cholinesterase-inhibitor in patients with mild to moderately severe Alzheimer's disease. For the ENA-713 (rivistigmine tartrate) B352 Study Group. Int J Geriatr Psychiatry. 1998;1:55–65.Google Scholar
27.Raskind, MA, Peskind, ER, Wessel, T, Yuan, W. Galantamine in AD. A six-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000;54:2261–2268.CrossRefGoogle Scholar
28.Giacobini, E. From the Calabar bean to Alzheimer therapy. In: Giacobini, E, ed. Cholinesterases and Cholinesterase-inhibitors. London, England: Martin Dunitz; 2000:181–226.Google ScholarPubMed
29.Samochocki, M, Zerlin, M, Jostock, R, et al.Galantamine is an allosterically potentiating ligand of the human a4/b2 nAChR. Acta Neurol Scand. 2000;(suppl 176):68–73.CrossRefGoogle Scholar
30.Sahakian, BJ, Owen, AM, Morant, NJ, et al.Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology (Berl). 1993;110:395–401.CrossRefGoogle Scholar
31.Alhainen, K, Helkala, E-L, Reinikainen, K, et al.The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrhydroaminoacridine in patients with Alzheimer's disease. J Neural Transm P-D Sect. 1993;5:185–192.CrossRefGoogle ScholarPubMed
32.Cummings, JL, Gorman, DG, Shapira, J. Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry. 1993;33:536–541.CrossRefGoogle ScholarPubMed
33.Gorman, DG, Read, SR, Cummings, JL. Cholinergic therapy of behavioral disturbances in Alzheimer's disease. Neuropsychiatry Neuropsychol Behav Neurol. 1993;6:229–234.Google Scholar
34.Cummings, JL, Mega, M, Gray, K, et al.The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44:2308–2314.CrossRefGoogle ScholarPubMed
35.Kaufer, DI, Cummings, JL, Christine, D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatr Neurol. 1996;9:1–6.CrossRefGoogle ScholarPubMed
36.Kaufer, DI, Cummings, JL, Christine, D. Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity. J Neuropsychiaty Clin Neurosci. 1998;10:55–63.CrossRefGoogle ScholarPubMed
37.Raskind, MA, Sadowsky, CH, Sigmund, WR, et al.Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer's disease. Arch Neurol. 1997;54:836–840.CrossRefGoogle Scholar
38.Morris, JC, Cyrus, PA, Orazem, J, et al.Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology. 1998;1222–1230.CrossRefGoogle ScholarPubMed
39.Tariot, PN, Solomon, PR, Morris, JC, et al.A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54:2269–2276.CrossRefGoogle ScholarPubMed
40.Feldman, H, Gauthier, S, Hecker, J, et al.A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001;57:613–620.CrossRefGoogle ScholarPubMed
41.McKeith, IG, Galasko, D, Kosaka, K, et al.Consensus guidelines for the clinical and pathological diagnosis of Dementia with Lewy bodies (DLB): report on the consortium on DLB international workshop. Neurology. 1996;47:1113–1124.CrossRefGoogle Scholar
42.Tiraboschi, P, Hansen, LA, Alford, M, et al.Cholinergic dysfunction in diseases with Lewy bodies. Neurology. 2000;54:407–411.CrossRefGoogle ScholarPubMed
43.McKeith, IG, Fairbairn, A, Perry, RH, et al.Neuroleptic sensitivity in patients with senile dementia of the Lewy body type, Brit Med J. 1992;305:673–678.CrossRefGoogle Scholar
44.Apaydin, H, Ahlskog, EA, Parisi, JE, Boeve, BF, Dickson, DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol. 2002;59:102–112.CrossRefGoogle ScholarPubMed
45.Hutchinson, M, Fazzini, E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1996;61:324–326.CrossRefGoogle ScholarPubMed
46.Werber, EA, Rabey, JM. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm. 2001;108:1319–1325.CrossRefGoogle ScholarPubMed
47.Reading, PJ, Luce, AK, McKeith, IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord. 2001;16:1171–1174.CrossRefGoogle ScholarPubMed
48.Aarsland, D, Larsen, JP, Janvin, C. Donepezil treatment in Parkinson's disease with dementia: a double-blind, placebo-controlled crossover study. Neurology. 2001;56(suppl 3):A128.Google Scholar
49.Kaufer, DI, Catt, K, Lopez, O, et al.Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology. 1998;51:1512.CrossRefGoogle ScholarPubMed
50.Aarsland, D, Bronnick, K, Karlsen, K. Donepezil for dementia with Lewy bodies: a case study. Int J Geriatr Psychiatry. 1999;14:69–72.3.0.CO;2-C>CrossRefGoogle ScholarPubMed
51.Shea, C, MacKnight, C, Rockwood, K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr. 1998;3:229–238.CrossRefGoogle Scholar
52.Lanctot, KL, Herrmann, N. Donepezil for behavioural disorders associated with Lewy bodies: a case series. Int J Geriatr Psychiatry. 2000;15:338–345.3.0.CO;2-U>CrossRefGoogle ScholarPubMed
53.Samuel, W, Caligiuri, M, Galasko, D, et al.Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry. 2000;15:794–802.3.0.CO;2-1>CrossRefGoogle ScholarPubMed
54.McKeith, IG, Del Ser, T, Spano, P, et al.Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356; 2031–2036.CrossRefGoogle ScholarPubMed
55.Ming, Chow Tsz, Kaufer, DI. Effect of donepezil on aphasia, agnosia, and apraxia in patients with cerebrovascular disease. J Neuropsychiatry Clin Neurosci. 2001[abstract];13:40.Google Scholar
56.Mendez, MF, Younesi, FL, Perryman, KM. Use of donpezil for vascular dementia: preliminary clinical experience. J Neuropsychiatr Clin Neurosci. 1999;11:268–270.CrossRefGoogle Scholar
57.Kumar, V, Anand, R, Messina, J, Hartman, R, Veach, J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol. 2000;7:159–169.CrossRefGoogle ScholarPubMed
58.Erkinjutti, T, Kurz, A, Gauthier, S, et al.Galantamine is efficacious in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease. Lancet. 2002; In press.Google Scholar
59.Kalaria, RN, Ballard, C. Overlap between pathology of Alzheimer's disease and vascular dementia. Alzheimer Dis Assoc Disord. 1999;13(suppl 3):S115–S123.CrossRefGoogle ScholarPubMed
60.Gottfries, CG, Blennow, K, Karlsson, I, Wallin, A. The neurochemistry of vascular dementia. Dementia. 1994;5:163–167.Google ScholarPubMed
61.Snowdon, DA, Greiner, LH, Mortimer, JA, et al.Brain infarction and the clinical expression of Alzheimer's disease. The Nun Study. JAMA. 1997;277:813–817.CrossRefGoogle ScholarPubMed
62.Mesulam, M-M. Large-scale neurocognitive networks and distributed processing for attention, language, and memory. Ann Neurol. 1990;28:597–613.CrossRefGoogle ScholarPubMed
63.Sunderland, T, Molchan, SE, Little, JT, Bahro, M, et al.Pharmacologic challenges in Alzheimer's disease and normal controls: cognitive modeling in humans. Alzheimer Dis Assoc Disord. 1997;11:S23–26.Google ScholarPubMed
64.Soininen, H, Unni, L, Shillcutt, S. Effect of acute and chronic cholinesterase inhibition on biogenic amines in rat brain. Neurochem Res. 1990;15:1185–1190.CrossRefGoogle ScholarPubMed
65.Soares, JC, Gershon, S. THA-historical aspects, review of pharmacological properties and therapeutic effects. Dementia. 1995;6:225–234.Google ScholarPubMed
66.Kaufer, DI. Alzheimer's disease: Focus on the cholinergic system. In: Perry, E, Ashton, H, Young, A, eds. Neurochemistry of Consciousness. Neurotransmitters in Mind. Amsterdam, Netherlands: John Benjamins; 2001:230–245.Google Scholar
67.Kuhl, DE, Koeppe, RA, Minoshima, S, et al.In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology. 1999;52:691–699.CrossRefGoogle ScholarPubMed